Aptevo Therapeutics(APVO) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Mr. White continued "We're pleased to report that our lead asset, mipletamig, continues to perform as designed in the clinic. In frontline acute myeloid leukemia (AML), 85% of evaluable patients Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfol ...